UK markets close in 5 hours 22 minutes

Celyad SA (CYAD)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.4200+0.0300 (+2.16%)
At close: 03:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.3900
Open1.4500
Bid1.3700 x 1000
Ask1.4500 x 900
Day's range1.4000 - 1.4500
52-week range1.2400 - 5.3200
Volume3,864
Avg. volume139,390
Market cap33.628M
Beta (5Y monthly)1.11
PE ratio (TTM)N/A
EPS (TTM)-1.5070
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.08
  • Business Wire

    Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction

    GOSSELIES, Belgium & MONT-SAINT-GUIBERT, Belgium, September 20, 2022--Regulatory News: Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice (GMP) grade cell therapy manufa

  • Business Wire

    Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

    MONT-SAINT-GUIBERT, Belgium, August 05, 2022--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced an update on its financial results and recent business developments for the first half ended June 30, 2022.

  • Business Wire

    Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial

    MONT-SAINT-GUIBERT, Belgium, August 01, 2022--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the CYAD-101-002 (KEYNOTE-B79) Phase 1b trial after the Company made changes to the eligibility criteria